Roivant Sciences Ltd. (ROIV) – What Are Brokerages Thinking About This Stock?

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have received a consensus rating of “Moderate Buy” from the fourteen analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $45.64.

A number of brokerages have recently issued reports on ROIV. Bank of America reiterated a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a research note on Wednesday, July 29th. Citigroup reissued a “buy” rating on shares of Roivant Sciences in a report on Monday. HC Wainwright upped their target price on shares of Roivant Sciences from $41.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, September 8th. Finally, Wolfe Research lowered shares of Roivant Sciences from an “outperform” rating to a “peer perform” rating in a research report on Monday.

Insider Transactions at Roivant Sciences

In related news, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $36.62, for a total value of $7,324,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,599,154 shares of the company’s stock, valued at $58,561,019.48. This trade represents a 11.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock in a transaction on Friday, August 21st. The stock was sold at an average price of $36.48, for a total value of $5,280,698.88. Following the transaction, the insider directly owned 18,630,739 shares of the company’s stock, valued at approximately $679,649,358.72. This represents a 0.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 1,622,688 shares of company stock valued at $58,826,636 in the last quarter. 8.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Roivant Sciences

Large investors have recently bought and sold shares of the company. Parallel Advisors LLC lifted its position in Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after buying an additional 520 shares in the last quarter. Bessemer Group Inc. grew its stake in Roivant Sciences by 21.8% during the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after buying an additional 441 shares during the period. Root Financial Partners LLC increased its position in shares of Roivant Sciences by 187.9% in the first quarter. Root Financial Partners LLC now owns 2,914 shares of the company’s stock worth $81,000 after acquiring an additional 1,902 shares in the last quarter. Acropolis Investment Management LLC acquired a new stake in shares of Roivant Sciences in the third quarter worth $134,000. Finally, Versant Capital Management Inc increased its position in shares of Roivant Sciences by 13.9% in the second quarter. Versant Capital Management Inc now owns 3,995 shares of the company’s stock worth $141,000 after acquiring an additional 487 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

Roivant Sciences stock opened at $33.35 on Wednesday. The stock’s 50 day moving average price is $36.70 and its 200 day moving average price is $32.95. Roivant Sciences has a 1-year low of $16.00 and a 1-year high of $42.50.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. The firm had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. As a group, sell-side analysts forecast that Roivant Sciences will post -2.00 EPS for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with serious or underserved diseases. The company operates through a network of subsidiary companies, known as “Vants,” each dedicated to specific therapeutic areas, drug candidates or commercial opportunities.

Roivant’s research and development activities have included treatments for immune-mediated diseases, rare disorders, oncology and conditions affecting the nervous system.